The approval makes Evrysdi the first and only tablet for treating spinal muscular atrophy.
Author - David Miller
EMA Earns EMAS Certification
The agency has received certification with the Eco-Management and Audit Scheme for its commitment...
Epitopea Strikes Research Collaboration with Merck, Appoints...
Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens...
Former Health Agency Heads React to Federal Layoffs at NIH, CDC...
Former leaders of the CDC, FDA, and other agencies condemned the layoffs.
Applyo Jena Closes Successful Series A Funding Round
Led by Bosch Ventures, Applyo Jena’s Series A funding seeks to accelerate the development and...
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell...
Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but...
How Collaborations Help Abpro’s Success
In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about...
Behind the Headlines Episode 11–GLP-1 Patent Expiry, Recent...
Benjamin McLeod, Abhi Naravane, PhD, MBA, and Marianna Tcherpakov PhD go behind the headlines to...
Pharma Pulse 2/20/25: Popping the Gross-to-Net Bubble, Prompting...
The latest news for pharma industry insiders.
Picking Markets for a Global Launch Strategy
John Arena, interim president of global pharma services at Cencora, discusses how companies must...